Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Site Tools

  • AAAS
  • Subscribe
  • Feedback

Site Search

Search Advanced

Science 10 August 2001:
Vol. 293. no. 5532, p. 1024
DOI: 10.1126/science.293.5532.1024
Prev | Table of Contents | Next

News of the Week

CLINICAL RESEARCH:
Hopkins Reviews Investment in Indian Cancer Drug Trial

Pallava Bagla and Eliot Marshall

Now add financial interest to the mix of combustible elements in the controversy over tests of a new drug for oral cancer in India. Johns Hopkins University, whose professor helped design a trial at the Regional Cancer Center of Trivandrum, India, has also invested in a Minnesota start-up medical company that plans to test the drug at other Asian sites. Hopkins is also trying to explain how it could have sent a check to support the cancer study in India without first seeking approval from a university ethics panel. (See Editorial in this issue.)

Read the Full Text


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
Doing cancer trials in India: opportunities and pitfalls.
V. Raina (2005)
Ann. Onc. 16, 1567-1568
   Full Text »    PDF »


ADVERTISEMENT
Click Me!

ADVERTISEMENT
Click Me!

To Advertise     Find Products

Science. ISSN 0036-8075 (print), 1095-9203 (online)